Impact of residual mitral valve regurgitation following septal myectomy for obstructive hypertrophic cardiomyopathy
The Journal of Thoracic and Cardiovascular Surgery · 2025-12 · 170 (6) · 1569-1579.e5
DOI: 10.1016/j.jtcvs.2025.03.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025-12. Verfasst von Younus Qamar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Mitral Valve Insufficiency, Cardiac Surgical Procedures, Heart Septum. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To evaluate the impact of residual mitral valve (MV) regurgitation (MR) in patients with obstructive hypertrophic cardiomyopathy immediately after myectomy on late survival and the risk of MV reintervention. METHODS: From October 2001 to February 2024, 3061 patients with hypertrophic cardiomyopathy and dynamic left ventricular outflow tract obstruction underwent septal myectomy. A 1:1 propensity score matching was performed between patients with mild or trivial/no residual MR immediately after cardiopulmonary bypass and patients with moderate or greater residual MR. Long-term survival, MR progression, and the incidence of MV reintervention were analyzed. RESULTS: Postbypass moderate or greater residual MR was present in 398 patients (13.9%). Matching yielded 398 pairs, with no differences in age (62.1 years vs 61.9 years, P = .397), nor in median peak left ventricular outflow tract gradient on predismissal echocardiography (3 [0-9] mm Hg vs 3 [0-10] mm Hg, P = .585). Late incidence of moderate-severe or greater MR was greater in those with residual MR (15 years: 48.0% vs 11.9%, P = .002), and the incidence of subsequent MV intervention at 15 years was 3-fold greater in those with intraoperative residual MR (14.0% vs 3.9%, P = .007). However, the overall survival of the 2 groups was similar (P = .48). CONCLUSIONS: Residual MR after septal myectomy is not associated with early or late mortality. However, beyond 5 years' postoperatively, patients with moderate or greater residual MR experience accelerated rates of recurrent MR and require MV reintervention. Residual MR may be attributable to unrecognized mild intrinsic MV disease that progresses late postoperatively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
- Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn. Electronic address: schaff@mayo.edu.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minn.
Zitieren
APA
Qamar, Y., Schaff, H. V., Geske, J. B., Dearani, J. A., Giudicessi, J. R., Todd, A., & Ommen, S. R. (2025). Impact of residual mitral valve regurgitation following septal myectomy for obstructive hypertrophic cardiomyopathy. The Journal of Thoracic and Cardiovascular Surgery, 170(6), 1569-1579.e5. https://doi.org/10.1016/j.jtcvs.2025.03.033
Vancouver
Qamar Y, Schaff HV, Geske JB, Dearani JA, Giudicessi JR, Todd A, et al. Impact of residual mitral valve regurgitation following septal myectomy for obstructive hypertrophic cardiomyopathy. The Journal of Thoracic and Cardiovascular Surgery. 2025;170(6):1569-1579.e5. doi:10.1016/j.jtcvs.2025.03.033
BibTeX
@article{Qamar2025,
author = {Qamar, Younus and Schaff, Hartzell V and Geske, Jeffrey B and Dearani, Joseph A and Giudicessi, John R and Todd, Austin and Ommen, Steve R},
title = {Impact of residual mitral valve regurgitation following septal myectomy for obstructive hypertrophic cardiomyopathy},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2025},
volume = {170},
number = {6},
pages = {1569--1579.e5},
doi = {10.1016/j.jtcvs.2025.03.033}
}
EUVIMED